

CHOICE MATTERS

EXPANDING THE METHOD MIX OF ARV-BASED PREVENTION FOR WOMEN IN 2012 AND BEYOND

Experience over decades of contraceptive development and use has demonstrated that women's preferences differ, and that a product that best suits a woman's lifestyle and needs is more likely to be used.

Will the same be true for HIV prevention?
If not, can we create demand?

CHOOSE TO BE PART OF THE DISCUSSION

Please join us for this interactive satellite session

THURSDAY, JULY 26, 6:30-8:30 PM

MINI ROOM 7, WALTER E. WASHINGTON CONVENTION CENTER

PROGRAM

Looking back, looking forward: What we know and don't know (but may soon find out) about oral PrEP and tenofovir gel for preventing HIV in women

JARED BAETEN, University of Washington, United States

Expanding the method mix: Current and planned trials of different ARV-based approaches for women

ZEDA ROSENBERG, International Partnership for Microbicides, United States

Does choice matter? Are we there yet? A review of the challenges ahead and probable timelines for oral Truvada, tenofovir gel and the dapivirine ring

SHARON HILLIER, Microbicide Trials Network, University of Pittsburgh, United States

Panel discussion: Making it real, making it happen

ALLIANCE NIKUZE, Health Department Initiative-Rwanda

PAMELA NJUGUNA, Kenya Medical Women's Association, Kenya

DAWN AVERITT BRIDGE, The Well Project, United States

NAINA KHANNA, WORLD and U.S. Positive Women's Network, United States

LIHLE DLAMINI, Treatment Action Campaign, South Africa

SESSION CO-CHAIRS – SHARON HILLIER, ZEDA ROSENBERG

MODERATOR – MITCHELL WARREN, AVAC: Global Advocacy for HIV Prevention

Please join us for an informal reception following the session

